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Abstract
Background: MicroRNA miR-155 is implicated in modulation of the inflammatory processes in various pathological
conditions. In our previous studies, we demonstrated that in vivo inhibition of miR-155 promotes functional
recovery after mouse experimental stroke. In the present study, we explored if this beneficial effect is associated
with miR-155 inhibition-induced alterations in post-stroke inflammatory response.
Methods: Intravenous injections of a specific miR-155 inhibitor were initiated at 48 h after mouse distal middle
cerebral artery occlusion (dMCAO). Temporal changes in the expression of cytokines and key molecules associated
with cytokine signaling were assessed at 7, 14, and 21 days after dMCAO, using mouse cytokine gene and protein
arrays and Western blot analyses. Electron and immunofluorescence confocal microscopy techniques were used to
evaluate the ultrastructural changes, as well as altered expression of specific phenotypic markers, at different time
points after dMCAO.
Results: In the inhibitor-injected mice (inhibitor group), there was a significant decrease in CCL12 and CXCL3
cytokine expression at 7 days and significantly increased levels of major cytokines IL-10, IL-4, IL-6, MIP-1α, IL-5, and
IL-17 at 14 days after dMCAO. These temporal changes correlated with altered expression of miR-155 target
proteins SOCS-1, SHIP-1, and C/EBP-β and phosphorylation levels of cytokine signaling regulator STAT-3. Electron
microscopy showed decreased number of phagocytically active peri-vascular microglia/macrophages in the
inhibitor samples. Immunofluorescence and Western blot of these samples demonstrated that expression of
leukocyte/ macrophage marker CD45 and phagocytosis marker CD68 was reduced at 7 days, and in contrast,
significantly increased at 14 days after dMCAO, as compared to controls.
Conclusions: Based on our findings, we propose that in vivo miR-155 inhibition following mouse stroke
significantly alters the time course of the expression of major cytokines and inflammation-associated molecules,
which could influence inflammation process and tissue repair after experimental cerebral ischemia.
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Background
Ischemic stroke triggers complex, multipart cascade of
events leading to irreversible brain damage and dysfunc-
tion of the neurovascular network in the ischemic core
[1]. Hypoxic but still viable peri-infarct area surrounding
the core region remains to be a subject of intensive
investigation, with the focus on neuroprotective and pro-
regenerative treatments for preservation of salvageable
brain tissue. Post-ischemic inflammatory response is an
integral part of both brain damage and recovery, yet its
function remains controversial. Lower levels of pro-
inflammatory cytokines and higher expression of anti-
inflammatory cytokines are associated with lower infarct
size and a better clinical outcome [2, 3]. On the other
hand, number of pro-inflammatory cytokines is implicated
in neuroprotection and post-stroke plasticity and, thus, in
facilitation of the restorative processes and tissue remodel-
ing [4, 5]. Original elevation of cytokine expression during
acute inflammation starts as early as several hours and is as-
sociated with recruitment of different types of cells into the
ischemic area, including neutrophils, lymphocytes, mono-
cytes, and activation of resident microglia, astrocytes, and
endothelial cells [3]. Activation of microglia and astrocytes
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leading to additional release of pro-inflammatory factors can
last for up to several weeks after stroke [5].
Ischemia is associated with significant changes in the
molecular profile of the neurovascular elements [6, 7].
Short messenger RNA (mRNA)-interfering molecules
microRNAs (miRNAs) are recently identified as essential
modulators of inflammatory response in the brain [8, 9].
Multifunctional miRNA miR-155 is among the miRNAs
with expression profiles significantly affected by cerebral
ischemia [10–12]. miR-155 has been implicated in regu-
lating various physiological and pathological processes
including immunity and inflammation [13, 14]. Recent
investigations identified miR-155 as a potent regulator of
the neuroinflammatory response in Japanese encephalitis
and Alzheimer’s disease [15, 16]. Microglia-mediated im-
mune response associated with several pathological
states is regulated by miR-155 [17–19]. Specific inhib-
ition of this miRNA is accompanied by reduced inflamma-
tion, in several pro-inflammatory conditions [20, 21]. miR-
155 mediates the inflammatory response through negative
targeting of its direct target proteins including Src
homology 2-containing inositol phosphatase 1 (SHIP-1)
[15, 22], suppressor of cytokine signaling molecules
SOCS-1 and SOCS-6 [19, 23, 24], and transcription factor
CCAAT/enhancer binding protein beta (C/EBP-β) [25].
All these miR-155-targeted factors control the inflamma-
tory response via suppression of cytokine transcription
and signaling.
In our previous study, we found that specific in vivo in-
hibition of miR-155 after experimental mouse ischemia
supports brain microvasculature in the peri-infarct area,
reduces brain tissue damage, and improves the animal
functional recovery. In addition, miR-155 inhibition after
distal middle cerebral artery occlusion (dMCAO) resulted
in alterations of several cytokine/chemokine gene expres-
sion [26], prompting our interest to possible role of miR-
155 in post-ischemic inflammation. miR-155 is expressed
in hematopoietic cells (including B cells, T cells, mono-
cytes, and granulocytes), endothelial cells, microglia, and
astrocytes [17, 23, 27]. All these cell types are able to ex-
press and secrete pro- and anti-inflammatory molecules
and, thus, actively participate in the inflammation process.
Therefore, we proposed that systemic in vivo inhibition of
miR-155 could significantly affect the post-stroke inflam-
matory response. While cytokine expression has been
mostly studied during the acute inflammation, few studies
have examined the temporal profile of pro- and anti-
inflammatory molecules during subacute phase of stroke.
The present investigation focuses on the long-lasting
effect of miR-155 inhibition on the inflammatory response.
To our knowledge, this is a first report describing the
effect of intravenous anti-miRNA injections on the time
course of cytokine expression and cellular inflammatory
response following mouse stroke.
Methods
Animal groups
All institutional and national guidelines for the care and use
of laboratory animals were followed during the experiments.
C57BL/6 male mice (2-month old, Jackson Laboratories;
https://www.jax.org/strain/000664) were used in our studies.
Experimental groups included sham-operated mice, mice
subjected to dMCAO and specific miR-155 inhibitor injec-
tions (inhibitor group), and mice subjected to dMCAO and
control (scrambled) miRNA inhibitor injections (control
group).
Distal middle cerebral artery procedure
A distal (direct) middle cerebral artery occlusion
(dMCAO) was utilized as an experimental model of cor-
tical ischemia [28]. dMCAO was performed on 2-month-
old male C57BL/6 mice, as described in [26]. The mice
were anesthetized using isoflurane gas (induction dosage
2–3 %; maintenance dosage 1.5–2 %) and a mixture of
O2:N2O gases in the ratio 2:1, delivered during the sur-
gery. The MCA was exposed via transtemporal approach
[28, 29]. A small burr hole (located 1 mm rostral to the fu-
sion of zygoma and squamosal bone and 3 mm ventral to
the parietal bone) was made on the left side of the skull
surface, and the MCA was coagulated with low-heat elec-
trocautery (Bovie Medical). In sham-operated animals, the
MCA was exposed but not coagulated.
miRNA inhibitor injections
Injections of specific anti-miR-155 miRCURY LNA™
(Product#4101082-001, https://www.exiqon.com/micro-
rna-knockdown-probes) inhibitor or control inhibitor
(scrambled oligonucleotide, Product#199006) from Exi-
qon Company were initiated at 48 h after dMCAO and
performed for three consecutive days. Oligonucleotides
were introduced via mouse lateral tail vein; the dose was
10 mg/kg in saline, total injected volume 100 μl [26].
Mouse cytokine and chemokine PCR array
Mouse cytokine and chemokine PCR array (Qiagen, Cat#
PAMM-150Z, http://www.sabiosciences.com/rt_pcr_pro-
duct/HTML/PAMM-150A.html) was utilized to evaluate
the expression of genes encoding major pro- and anti-
inflammatory cytokines and chemokines in the RNA
samples. At 7 days after dMCAO, three brains per experi-
mental group (inhibitor and control) were used to generate
separate sample triplicates for the analyses. Brain cortices
were dissected and stored in RNAlater solution (Ambion).
Total RNA was isolated using mirVana miRNA (AB/
Ambion) isolation kit, from the hemispheres ipsilateral to
dMCAO injury. All measurements and data quantification
were performed by Qiagen Company Sample & Assay
Technologies team. The obtained raw data were analyzed
using RT2 Profiler software (Qiagen). Only the genes with
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consistent expression levels (within the triplicate samples)
were picked up for statistical analysis. The fold changes of
gene expressions (inhibitor vs control) were calculated, and
the transcripts that showed ≥2-fold change in expression (ei-
ther up- or downregulated) were retained. At the final step,
statistical significance (p value <0.05) and reliability of the
results was automatically evaluated. The raw data are depos-
ited in the Open Science Framework general data repository,
link: https://osf.io/3zhc4/?view_only=0826f6e687884b90ab7
74328c2746ae1.
Cytokine protein expression analysis
At 48 h and 7, 14, and 21 days after dMCAO, six brains per
experimental group (sham, inhibitor, and control) were used
to generate separate samples. Brain cortices from both ipsi-
and contralateral (to dMCAO damage) hemispheres were
dissected on ice and rapidly frozen. Lesioned and intact
hemispheres were analyzed separately. Brain tissue was
homogenized in tissue extraction buffer (Life Tech/Invitro-
gen Cat# FNN0071, 5 ml per 1 g of brain tissue) with the
addition of protease inhibitor cocktail (Sigma). The samples
were centrifuged at 10,000 rpm for 5 min, and supernatant
was collected and kept on ice. Protein concentration was de-
termined for each sample, using DC protein assay kit from
BioRad. Brain tissue samples were normalized for total pro-
tein content and diluted at 1:10 in assay buffer. Expression
levels of CCL12 and CXCL3 were detected using Mouse
CCL12/MCP5 PicoKine™ (Boster Biological Technology,
Cat# EK1128) and Mouse CXCL3 PicoKine™ ELISA Kits
(Boster Biological Technology, Cat# EK1364), according to
manufacturer’s recommendations. Other cytokine protein
expression was detected using Mouse Cytokine Magnetic
20-Plex Panel Kit (Life Tech/Invitrogen, Cat# LMC0006M,
https://www.thermofisher.com/order/catalog/product/LMC
0006M), according to the manufacturer’s recommendations.
The Panel is designed for the quantitative determination of
FGF-basic, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, IP-10, KC, MCP-
1, MIG, MIP-1α, TNF-α, and VEGF expression. The mea-
surements were done using Luminex xMAP-100 system, at
the UNM Center of Molecular Discovery. Cytokine concen-
trations were calculated automatically, using Specialized
Luminex system software. For quantification, only cytokines
with consistent expression throughout the samples were
retained. Two-way ANOVA followed by Tukey’s multiple
comparison test was used for final statistical analysis. The
raw data are deposited in the Open Science Framework
general data repository, link: https://osf.io/dz5ue/
?view_only=4f2c586e7562432595d894b86154b97e.
Western blot analysis
Five to six brains per experimental group were collected
at 7, 14, and 21 days after dMCAO and used to generate
separate samples. Brain cortices from ipsi- and
contralateral (to dMCAO damage) hemispheres were
dissected on ice and rapidly frozen. For tissue lysate
preparation, brain tissue was homogenized in tissue ex-
traction buffer (Life Tech/Invitrogen Cat# FNN0071,
5 ml per 1 g of brain tissue) with the addition of prote-
ase inhibitor cocktail (Sigma). The samples were centri-
fuged at 10,000 rpm for 5 min, and supernatant was
collected and kept on ice. Protein concentration was de-
termined for each sample, using DC protein assay kit
from BioRad. The proteins were separated on 4–20 %
gradient Criterion precast gels (Bio-Rad). A broad range
molecular weight calibration marker from 10,000 to
250,000 MW (Bio-Rad) was used as a standard. Janus
kinase (JAK)/signal transducer and activator of tran-
scription (STAT) signaling pathway analysis was per-
formed using phospho-STAT antibody sampler kit (Cell
Signaling Technology Cat#9914, RRID:AB_330385).
Other antibodies used were as follows: mouse monoclo-
nal anti-STAT-3 (Cell Signaling Technology Cat# 9139,
RRID:AB_331757); rabbit polyclonal anti-SOCS-1 (Cell
Signaling Technology Cat# 3950S, RRID:AB_2192983);
anti-SHIP-1 (Cell Signaling Technology Cat# 2728, RRI-
D:AB_2126244); anti-C/EBP-β (Cell Signaling Technol-
ogy Cat# 3087, RRID:AB_2078052); rabbit polyclonal
anti-SOCS-6 (Santa Cruz Biotechnology Cat# sc-5608,
RRID:AB_661195); rabbit polyclonal anti-Iba-1 (Wako
Cat# 019-19741, RRID:AB_839504); rat anti-mouse
CD68 (AbD Serotec Cat# MCA1957, RRID:AB_322219);
goat polyclonal anti-CD206 (R and D Systems Cat#
AF2535, RRID:AB_2063012); and anti-CD45 (R and D
Systems Cat# AF114, RRID:AB_442146). Loading was
confirmed by comparing actin immunoreactivity across the
lanes, using mouse monoclonal anti-actin (Sigma-Aldrich
Cat# A2228, RRID:AB_476697). Horseradish peroxidase-
labeled secondary antibodies were from Cell Signaling and
Amersham Biosciences. The density of the protein bands
was determined using ImageJ software (NIH Image,
RRID:SCR_003073), normalized by actin expression and
quantified using Microsoft Excel software.
Immunohistochemistry and fluorescence microscopy
The animals were perfused with PBS and 4 % parafor-
maldehyde (PFA); brains were removed and fixed in PFA
and subsequently cryoprotected in 30 % sucrose. The
brains were sectioned along the rostral-caudal axis;
16 μm coronal sections were mounted and subjected to
immunostaining. Briefly, the slices were post-fixed with
4 % PFA and quenched with 50 mM NH4Cl. For antigen
retrieval, the mixture of 1 % antigen unmasking solution
(Vector Laboratories Cat# H-3301, RRID:AB_2336227)
and 10 % of 1 M sodium citrate in PBST (PBS contain-
ing 0.05 % Triton X-100) was boiled, and tissue slices
were immersed in the mixture for 15 min. Ten percent
normal goat serum containing 0.05 % Triton-X was used
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as a blocking buffer. The slides were subsequently incu-
bated with primary antibodies, at 4 °C overnight. Following
antibodies were used for the immunostaining: rabbit poly-
clonal anti-Iba-1 (Wako Cat# 019-19741, RRID:AB_839504);
mouse monoclonal anti-GFAP (BD Biosciences Cat#
556328, RRID:AB_396366); Cy-3-conjugated anti-NeuN
(Millipore Cat# ABN78C3, RRID:AB_11204707); goat
polyclonal anti-CD206 (R and D Systems Cat# AF2535,
RRID:AB_2063012); anti-CD45 (R and D Systems Cat#
AF114, RRID:AB_442146); and Alexa Fluor 488-
conjugated rat anti-mouse CD68 (AbD Serotec Cat#
MCA1957A488, RRID:AB_324822). FITC-, rhodamine-,
and Cy-5-conjugated secondary antibodies (1:200 concen-
tration, 2 h at RT) were from Jackson Immunoresearch.
DAPI staining was used to visualize nuclei. The incuba-
tions were performed in the humidity chamber.
Quantification of the immunofluorescence staining intensity
Mouse brain coronal sections co-immunostained for
Iba-1/CD206/DAPI or Iba-1/CD45/CD68 were imaged
using single-scan and tile-scan imaging on Zeiss
LSM510-META and Zeiss LSM-800 Airyscan confocal
microscopes. Tile-scan (10 × 15 tiles) imaging performed
with ×40 and ×60 magnification allowed us to acquire
high-resolution scans of the entire infarct core and peri-
infarct areas in the injured hemisphere, as well as to
capture a corresponding area in the contralateral hemi-
sphere. Occasionally, Z-stack imaging was used to localize
and confirm the intracellular labeling. Three to four cor-
onal sections from the rostral part of the brain (mostly af-
fected by dMCAO) per mouse (N = 5–6 per experimental
group/per time point) were imaged and quantified. ImageJ
software (NIH Image, RRID:SCR_003073) and a modified
fluorescence intensity quantification method described in
[30, 31] were used for quantification. The brain area of the
same size throughout all images (945 × 387 pixels, corre-
sponding to ~500 × 200 μm), including the edge of the in-
farct (glial scar) and part of the peri-infarct region, was
selected and analyzed. The following formula was used for
calculations: Corrected total fluorescence of the area =
total fluorescence intensity of the selected area − (selected
area ×mean fluorescence of background readings).
Electron microscopy
Mice were perfused with 0.5 % glutaraldehyde and 2.5 %
paraformaldehyde in 0.1 M Sorensen’s buffer. Cortical
tissue (1 × 1 mm) samples were fixed in 2 % osmium, dehy-
drated, embedded in Araldite, thin-sectioned to 80–90 nm,
and stained with 4 % uranyl acetate in methanol followed
by lead citrate as described in [26, 32]. Images were ac-
quired using Hitachi H7500 Transmission Electron Micro-
scope equipped with AMT X60 camera. Three to four
animals per experimental group (control and inhibitor)
were used for analysis; high magnification (×800–15,000)
images were taken both in the lesioned and intact
hemispheres.
Statistical analysis
PCR array data were analyzed using RT2 Profiler soft-
ware (Qiagen). The p values were calculated based on a
Student’s t test of the replicate 2^(−Delta Ct) values for
each gene in the control and inhibitor groups. Statistical
analysis for all other obtained data was performed using
Prism and GraphPad Prism v.6.05, or R software. Two-
way ANOVA followed by Tukey’s multiple comparison
test was used for cytokine protein expression analysis.
Student’s t test was performed for the Western blot, im-
munofluorescence microscopy, and electron microscopy
data analyses.
Results
In our previous study, we characterized miR-155 inhib-
ition efficiency following intravenous injections after
mouse dMCAO. Specific anti-miR-155 miRCURY™ LNA
inhibitor (Exiqon) probes crossed BBB and were identi-
fied both in the blood vessels and brain tissue. RT-PCR
detected ~50 % inhibition of miR-155 expression, which
lasted for 7 days after the last injection. The functional
efficiency of the in vivo miR-155 inhibition was verified
by profiling miR-155 target gene and protein expressions
[26]. The same injection procedures were performed in
the present study: one group of the dMCAO animals re-
ceived intravenous injections of specific miR-155 inhibi-
tor (inhibitor group), another group—control scrambled
oligonucleotide (control group), at 48 h after dMCAO.
Injections lasted for three consecutive days. This period of
intervention was chosen based on the time course of post-
stroke revascularization and inflammation processes.
Since miR-155 inhibition is known to have an anti-
inflammatory action, we aimed to avoid influencing the
acute phase of post-stroke inflammation as an initiator of
constructive events, such as activation of microglia and as-
trocytes, vascular remodeling, and activation of endogen-
ous stem cells. In addition, the intravenous injections
would be more effective after the partial restoration of
BBB during a subacute phase following dMCAO.
miR-155 inhibition after dMCAO has a long-term effect on
cytokine expression profile
Initially, we investigated the effect of miR-155 inhibition
on the expression of genes encoding pro- and anti-
inflammatory factors, at 7 days following dMCAO.
Specialized cytokine/chemokine PCR profiler array was uti-
lized for this study. In accordance with already reported data
[26], gene profiling revealed a significant (>2-fold; p < 0.05)
downregulation of two cytokine genes, including pro-
inflammatory chemokine ligand 12 (Ccl12) and chemokine
ligand 3 (Cxcl3) (Fig. 1a, and blue symbols on Fig. 1b).
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Among the upregulated genes, increased expression of
genes encoding bone morphogenetic protein 4 (Bmp4), car-
diotrophin 1 (Ctf1), interleukin-23 subunit alpha (Il-23a),
and interleukin-17 (Il-17) were statistically significant but
less than twofold different from the control group samples.
Colony stimulating factor-3 gene (Csf3), chemokine (C-X-C
motif) ligand-9 gene (Cxcl9), and pro-platelet basic protein
gene (Ppbp) were increased more than twofold, and
interleukin-10 gene (Il-10) was upregulated fourfold (Fig. 1a
and orange symbols on Fig. 1b), but these elevations were
not consistent throughout all samples. mRNA levels of other
cytokines in the array were not different between control
and inhibitor groups (Fig. 1a, b). We then assessed protein
expression of CCL12 and CXCL3 cytokines in the control
and inhibitor groups (six mice per group), using specialized
quantitative ELISA detection kits. The measurements were
performed at 48 h (before the inhibitor injections) and 7, 14,
and 21 days after dMCAO. CCL12 concentration at 48 h
post-dMCAO was ~5550 pg/mL and decreased in both
groups at 7, 14, and 21 days. Protein measurements sup-
ported our gene expression data, showing that at 7 days after
dMCAO, CCL12 had significantly (1.8-fold) lower expres-
sion in the samples from the inhibitor group, as compared
to controls (Fig. 1c, left panel). Similarly, at 7 days after
stroke, CXCL3 protein levels were lower in the inhibitor
group, as compared to controls; this decrease was consistent
throughout all samples and statistically significant (Fig. 1c,
right panel). At 14 and 21 days, the cytokine concentrations
were similar between the groups (Fig. 1c).
Protein expression of other major pro- and anti-
inflammatory cytokines was measured using Mouse
Cytokine Magnetic 20-Plex Panel Kit (Life Tech/Invitro-
gen), at 48 h and 7, 14, and 21 days after dMCAO. The
measurements of 20 different cytokine expressions were
Fig. 1 Cytokine expression changes at 7 days after dMCAO. a Cytokine gene profiling at 7 days after dMCAO, inhibitor versus control groups.
Clustergram of 84 common cytokines grouped by sample type (i1, i2, i3—samples collected from three different mice from the inhibitor group.
c1, c2, c3—three samples from control group). Non-supervised hierarchical clustering was used to display common cytokine gene expression by
heat map visualization, with dendrograms indicating coregulated genes across groups or individual samples. Results for two statistically different
(between inhibitor and controls) genes Ccl12 and Cxcl3 are enlarged and showed in the bottom left corner. A color bar (bottom) relates color code
to the magnitude of the differences in gene expression relative to the all-sample means for each gene. The results are also demonstrated in the form
of scatter plots (b) of 84 common cytokine assays, revealing four upregulated and two downregulated genes (with more than twofold difference in
expression between the inhibitor and control groups). Orange symbols identify upregulated genes, and blue symbols identify downregulated genes.
c Protein expression levels of CCL12 and CXCL3 cytokines were assessed in the lesioned hemispheres of the animals from control (red plots) and
inhibitor (blue plots) groups at 7,14, and 21 days after dMCAO, using specialized Mouse CCL12 and CXCL3 PicoKine™ ELISA kits (Boster Biological
Technology). Cytokine expressions were also measured in the lesioned hemisphere of dMCAO-subjected mice at 48 h post-dMCAO (orange diamond).
N = 6 mice per group/per time point. Two-way ANOVA followed by Tukey’s multiple comparison test; *p < 0.05. Error bars: SEM
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performed in the tissue extracts collected from lesioned
(L, ipsilateral to dMCAO injury) and unlesioned (U,
contralateral to dMCAO injury) hemispheres of mice
from control and inhibitor groups (six mice per group/per
time point). Sham group (three animals per time point)
did not receive any injections. In order to measure the
cytokine profiles before the initiation of miR inhibition,
six dMCAO and six sham-operated animals were
sacrificed at 48 h after dMCAO. The major differences be-
tween control and inhibitor groups were detected at
14 days after dMCAO. At this time point, the expression
of six cytokines was consistently higher in the lesioned
hemispheres of the mice from the inhibitor group (thick
blue line plots), as compared to controls (thick red plots,
Fig. 2). Among significantly upregulated proteins were
anti-inflammatory interleukins IL-10 and Il-4 [33, 34];
cytokines with context-dependent dual (both anti- and
pro-inflammatory) action, including interleukins Il-6, IL-5,
and Il-17 [35–37]; and pro-inflammatory macrophage
inflammatory protein-1 family member MIP-1α [38]. At
48 h post-dMCAO, cytokine concentrations in the lesioned
hemisphere of dMCAO animals were not significantly dif-
ferent from the sham group (Fig. 2, orange diamonds and
grey triangles, respectively). This was expected since, accord-
ing to the existing literature, cytokine levels initially peak at
several hours after ischemia and, in most cases, return to
the basic levels by 24–48 h [39]. Cytokine expression in the
ipsilateral hemispheres of the inhibitor and control groups
significantly increased at 7 days, followed by a notable de-
crease (almost to the basic levels) at 21 days after dMCAO
(Fig. 2). Accordingly, in the inhibitor samples, IL-10 in-
creased fivefold at 7 days after stroke, as compared to ex-
pression at 48 h. Delayed (6–7 days) elevation of IL-10, IL-4,
and IL-17 in the post-acute phase of stroke was previously
reported by other authors [40, 41]. In control group, cyto-
kine concentrations peaked at 7 days after dMCAO and
steadily declined at 14 and 21 days (Fig. 2, thick red plots).
In contrast, in the inhibitor group, the concentration of all
these cytokines retained peak expression at both 7 and
14 days after dMCAO (Fig. 2, thick blue line plots). Cyto-
kine concentrations in the sham group (dark grey plots) also
increased at 7 days (with the exception of IL-10) but, until
21 days, remained significantly lower than in the lesioned
hemispheres of both inhibitor and control groups. At
21 days, cytokine expression in the lesioned hemispheres
was similar between dMCAO and sham animals. IL-10 ex-
pression returned to the basic levels, while other cytokines
remained slightly elevated at this time point. Cytokine ex-
pression in the unlesioned hemispheres of both inhibitor
and control groups (light blue and red plots, respectively)
Fig. 2 miR-155 inhibition results in long-term changes in cytokine profiles. Protein expression of 20 major pro- and anti-inflammatory cytokines was
measured using Mouse Cytokine Magnetic 20-Plex Panel Kit (Life Tech/Invitrogen), at 48 h and 7, 14, and 21 days after dMCAO. Samples were collected
from lesioned (thick red and blue plots) and unlesioned hemispheres (light red and blue plots) of mice from control and inhibitor groups, respectively.
Sham group (dark grey plots) did not receive any injections. dMCAO and sham-operated animals were used to measure cytokine expressions at 48 h
after dMCAO (orange diamond and grey triangle). N = 6 mice per group/per time point. Two-way ANOVA followed by Tukey’s multiple comparison test;
*p < 0.05, **p < 0.01. Error bars: SEM
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remained significantly lower than in the lesioned hemi-
spheres. To summarize, the expression of IL-10, IL-6, MIP-
1α, IL-5, IL-4, and IL-17 significantly increased in the le-
sioned hemisphere at 7 days after dMCAO. In contrast to
control animals, in the inhibitor group, high concentration
of all six cytokines remained for up to 14 days after stroke.
At this time point, the levels of these cytokines were
significantly higher in the inhibitor group, as compared to
controls.
miR-155 inhibition results in the impaired cytokine
signaling
In order to examine possible molecular mechanisms
underlying the effect of miR-155 inhibition on cytokine
profiles, we evaluated the expression of key cytokine sig-
naling regulator proteins, in the lesioned hemispheres of
the animals from the inhibitor and control groups, at 7,
14, and 21 days after dMCAO. The activity of JAK/
STAT signaling cascade, a key regulator of cytokine sig-
naling, was evaluated using phospho-STAT antibody
sampler kit (Cell Signaling). In addition, we examined
the expression of direct miR-155 targets, including cyto-
kine signaling suppressors SOCS-1, SOCS-6, SHIP-1,
and C/EBP-β. At 7 days after dMCAO, expression of
phospho-STAT-3 (phosphorylated at Tyr705) was con-
sistently and significantly decreased in the samples from
the inhibitor group, indicating decreased activity of
STAT-3 and, thus, STAT-3-regulated cytokine signaling
(Fig. 3a, left panel and graph). Reduced phosphorylation
(activity) of STAT-3 was accompanied by the elevated
SHIP-1 and SOCS-1 (negative regulator of STAT-3) in
these samples (Fig. 3a, left panel and graph). Since the
expression of SOCS proteins is very low in the adult
brain, a higher protein loading was required for their
analysis. Right panel of Fig. 3a demonstrates that the ex-
pression of another STAT regulator SOCS-6 was not
substantially affected by miR-155 inhibition, although
high molecular weight (82 kDa) isoform of this protein
was increased ~1.7-fold in the inhibitor samples, as
compared to controls. miR-155 target protein C/EBP-β
was significantly increased in the samples collected from
the inhibitor-injected animals. While STAT-3 phosphor-
ylation was reduced in the inhibitor samples, STAT-3
protein levels were similar between the groups (Fig. 3a,
right panel and graph). We conclude that at 7 days after
dMCAO, miR-155 inhibition may suppress cytokine signal-
ing via its direct targets SOCS-1 and SHIP-1. At 14 days
following dMCAO, there was a reversal in the STAT-3
activation, with now increased phospho-STAT-3 levels in
the inhibitor group (Fig. 3b). Importantly, changes in STAT-
3 phosphorylation occurred on Tyr705 residue, which is
exclusively affected by JAK-associated cytokine-stimulated
receptor signaling [42]. Phosphorylation of other STAT pro-
teins (including STAT-1, STAT-2, STAT-5, and STAT-6)
was not clearly detectable in our samples. C/EBP-β
remained upregulated in the inhibitor samples. At the same
time, the levels of SOCS-1 and SOCS-6, as well as SHIP-1,
were similar between the inhibitor and control samples
(Fig. 3b). This is in agreement with our findings that in vivo
miR-155 inhibition lasts for 10 days after the inhibitor injec-
tions, meaning that the microRNA levels were restored by
14 days after dMCAO. Increased phosphorylation of STAT-
3 in the inhibitors at this time point can be explained by
reduced suppression from SOCS proteins, as well as by in-
creased signaling of STAT-3 activator interleukin IL-10. In
turn, IL-10 increase may be induced by the elevated C/EBP-
β. At 21 days after dMCAO, no significant differences were
detected in STAT-3 phosphorylation, or in the expression
levels of SOCS-1 and C/EBP-β, between inhibitor and con-
trol groups (Fig. 3c). Expressions of SOCS-6 and SHIP-1 in
these samples were undetectable. In conclusion, at 7 days
after dMCAO, miR-155 inhibition resulted in de-activation
of STAT-3, which signifies suppression of STAT-3-mediated
cytokine signaling. In contrast, at 14 days after dMCAO,
there was an activation of STAT-3 in the miR-155 inhibitor-
injected animals. Prolonged elevation of anti-inflammatory
IL-10 (possibly facilitated by still upregulated C/EBP-β) and
pSTAT-3 could trigger IL-10/STAT-3-mediated anti-
inflammatory response. No differences between the animal
groups were detected at 21 days after dMCAO, which corre-
lates with our cytokine expression analysis.
Temporal distribution of microglia and astrocytes after
dMCAO
Immunofluorescence microscopy was used to assess the
distribution and phenotype of the cells responsible for
post-stroke inflammatory response, including microglia/
macrophages and astrocytes (the term microglia/macro-
phages will be substituted with microglia/macrophages
(M/Ms), throughout the text). At 48 h following dMCAO,
activated microglia were seen throughout whole ipsilateral
(lesioned) hemisphere (Fig. 4b). Hypertrophic cells with a
strong expression of microglia marker Iba-1 were substan-
tially different from the resting ramified microglia in the
contralateral hemisphere (Fig. 4a). In the peri-infarct area,
hypertrophied microglia exhibited bushy morphology,
which gradually transformed into mostly ameboid pheno-
type in the vicinity of the infarct edge (Fig. 4c). At 7, 14,
and 21 days, hypertrophied activated microglia were
mostly restricted to the peri-infarct zone. Glial scar was
well established by 7 days following dMCAO and con-
sisted of ameboid microglia (predominantly in the inner
border zone) and more peripherally localized reactive as-
trocytes (Fig. 4d–f ). There was a significant infiltration of
Iba-1-positive M/Ms into the infracted tissue (Fig. 4d;
I—infarct core, infarct edges are marked with arrow-
heads). Based on the literature, these invading cells mostly
consist of the macrophages, which are recruited and
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activated by the hypoxic/ischemic environment of the in-
farct core [43]. At 21 days post-MCAO, glial scar was
narrowed down, and both M/Ms and astrocytes of the
peri-infarct zone exhibited lower degree of reactivity, as
compared with 7 days after stroke (Fig. 4g, h). Most of the
activated M/Ms and astrocytes remained at the edge of in-
farct, in the area of the white matter (Fig. 4i). The distribu-
tion of microglia and astrocytes was similar between the
inhibitor and control groups, at all examined time points
after dMCAO.
Ultrastructural changes associated with miR-155
inhibition
Electron microscopy studies were performed for detailed
evaluation of the microglia and astrocyte phenotype in
the peri-infarct area of stroke. In previous studies, we re-
ported discrete electron microscopic changes in struc-
tural elements of the peri-infarct area of stroke observed
for as long as 21 days following dMCAO. These changes
included damaged and collapsed microcapillaries with
disrupted tight junctions at 7 days, followed by a
Fig. 3 miR-155 inhibition affects cytokine signaling machinery. a Left panel: Western blot analysis of phospho-STAT-3, SOCS-1, and SHIP-1 expression in
lysates prepared from the cortical tissue of the animals from inhibitor and control groups, at 7 days after dMCAO. Graphs represent WB quantification
analysis; Optical density of each band was normalized to β-actin (loading control). The samples were collected from the lesioned hemispheres of five
different mice per group. Right panel: higher quantity of the samples described in a was loaded in order to detect and quantify phospho-STAT-3,
STAT-3, SOCS-6 (with two corresponding 62 kDa (lmw) and 82 (hmw) bands), and C/EBP-β proteins. Graphs represent quantification of the relative
density representing protein expression normalized to actin expression (N = 5–6 animals per group). b, c p-STAT, STAT-3, SOCS-1, SOCS-6, SHIP-1, and
C/EBP-β protein expressions were detected and quantified in the samples collected from the lesioned hemispheres of the inhibitor and control animals
at 14 (b) and 21 (c) days after dMCAO. N = 5–6 animals per group. At 21 days, the expression levels of SOCS-6 and SHIP-1 were undetectable (not
shown). For all graphs: error bars: SEM; Student’s t test, *p < 0.05
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significant neuronal damage at 21 days after dMCAO.
We demonstrated that miR-155 inhibition supported ca-
pillary integrity and prevented prolonged neuronal death
in the peri-infarct area [26]. The present study was fo-
cused on the ultrastructure of the brain tissue elements
involved in post-stroke inflammatory response. Perivas-
cular M/Ms were seen in close vicinity of the capillaries
(Fig. 5a–d). In the control group, perivascular M/Ms
were often increased in size and characterized by intense
phagocytic activity. The cytoplasm of these hypertrophied
cells contained rich lysosomal apparatus with well-
developed lipophagosomes and numerous lipofuscin-like
deposits (Fig. 5c, d). In total, 90 capillaries in the control
group and 114 capillaries in the inhibitor group were im-
aged and analyzed. The quantification analysis revealed
that 14 % of the examined capillaries in the control group
was accompanied by the perivascular M/Ms with high
phagocytic activity. In contrast, only 3.5 % of capillaries in
the inhibitor group (significantly lower as compared to
controls, p < 0.05) were associated with the perivascular
phagocytic cells. According to the literature, phagocyti-
cally active perivascular microglia contribute to disintegra-
tion of BBB during the post-stroke inflammation [44].
Therefore, perivascular M/M quantification data are in
Fig. 4 Fluorescence microscopy analysis of the cellular inflammatory response during the subacute phase of stroke. Coronal sections of the
unlesioned (a) and lesioned (b, c) hemispheres of mice subjected to dMCAO, at 48 h after surgery. The sections were immunostained with anti-Iba-1
antibody (red). c Peri-infarct area of stroke; Infarct core (I) is outlined with white dotted line. Note the transformation of microglial phenotype from
ramified to hypertrophic bushy and ameboid, as their position is closer to the infarct border. d–f 7 days after dMCAO. Triple immunostaining with the
antibodies against GFAP (blue), Iba-1 (green), and NeuN (red). d Infarct core (I), glial scar, and peri-infarct area. The edge of the infarct is marked with
white arrowheads. e, f Higher magnification images demonstrate the distribution of microglia (green), astrocytes (blue), and neurons (red) in the
peri-infarct area and the immediate vicinity to glial scar. g–i 21 days after dMCAO. g The infarct core (I), glial scar, and peri-infarct area. The edge of the infarct
is marked with white arrowheads. Higher magnification images demonstrate the distribution of microglia (green), astrocytes (blue), and neurons (red) in the
peri-infarct area (h). Note the narrowing of the glial scar and its concentration mainly in the white matter area (i). Imaging was performed using Zeiss
LSM510-META confocal microscope, using single-scan and tile-scan image acquisitions. Bars: a–c 20 μm; d, g 100 μm; e, h 10 μm; f, i 50 μm
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Fig. 5 Ultrastructural characteristics of microglia and astrocytes during subacute phase of post-stroke inflammation. Representative transmission
electron microscopy images of capillaries, neurons, microglia, and astrocytes in the peri-infarct area of stroke, at 7 and 21 days after dMCAO, in
the inhibitor and control animals. a–d At 7 days post-dMCAO, perivascular M/Ms were seen in the vicinity of the microvessels. Note the signs of
significant phagocytic activity of the perivascular microglia in the control group, with characteristic large lysosomal inclusions in the cytoplasm
(c, d). e–h Perineuronal microglial cells were seen adhered to the healthy-looking neurons in the inhibitor group (e, f) and damaged necrotic
neurons in the control group (g, h), at 7 and 21 days after dMCAO. Microglia nuclei contained distinctly accumulated dense heterochromatin.
g Microglial cell invaded the damaged neuron. Neuronal cytoplasm has dispersed and disrupted organells and swollen mitochondria. i–l Swollen activated
perineuronal and perivascular astrocytes were seen in both groups, at 7 and 21 days after dMCAO. The astrocytes were characterized by dispersed residual
organelles and swollen mitochondria. Astrocyte fusion was often observed (k).m, n Significant edema and neuronal necrosis were observed at 21 days in
control animals, with multiple necrotic neurons, collapsed blood vessels, and heavily vacuolated brain tissue (n). In contrast, visibly less damaged brain tissue
was observed in the animals from the inhibitor group. Note healthy-looking neurons, intact and functional microvessels, and overall normal appearance of
neuropil (m). M microglia/macrophage, BV blood vessel, EC endothelial cell, Per pericyte, Lys lysosome, L lipofuscin-like deposit, N neuron,
A astrocyte, *—astrocytic process, m—mitochondria. Bars: a–h 1 μm; i–l 2 μm, and m, n 5 μm. Original magnifications: a–l ×1500–7000
and m, n ×800
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agreement with our previous findings that at 7 days after
stroke, vascular permeability was significantly lower in the
inhibitor group, as compared with controls [26]. Activated
microglial cells were frequently present in a close vicinity
of neuronal soma (Fig. 5e–h). In the control groups, peri-
neuronal microglia tightly adhered to and often invaded
the degenerating “dark” neurons (Fig. 5g, h). Electron
microscopic alterations in astroglia were similar between
the control and inhibitor groups and included significant
swelling and degenerative changes in astrocytic perikarya
and their processes; these pathological changes were seen
in perivascular astrocytes, as well as in the astrocytes ad-
hering to neurons or distributed in the neuropil. The cyto-
plasm of the remarkably swollen astrocytes was sometimes
completely empty, with dispersed residual organelles and
swollen mitochondria (Fig. 5i–l). In the control group, swol-
len astrocytes adhered to damaged and necrotic neurons
(Fig. 5l). Micrographs on panels m and n demonstrate the
neurons, capillaries, and neuropil in the peri-infarct area of
the brains from the inhibitor (m) and control (n) groups, at
21 days after stroke. In agreement with our previous studies,
in the inhibitor group, these brain tissue elements have less
damaged and more viable appearance. In contrast, in the
control group, we observed substantial number of necrotic
and damaged neurons, collapsed blood vessels, and signifi-
cant tissue edema. These observations are in agreement with
our previous findings demonstrating 46 % lower amount of
damaged neurons, and 21 % lesser collapsed blood vessels in
the inhibitor group as compared with controls, at 21 days
after dMCAO [26]. Thus, in the inhibitor animals, lower
number of phagocytically active perivascular M/Ms corre-
lates with stabilized microvasculature, decreased brain tissue
edema, and reduced neuronal damage.
Effect of miR-155 inhibition on the expression
of phenotypic markers
miR-155 is known to regulate a differentiation process
in microglia and macrophages [19, 45]. We therefore in-
vestigated the effect of in vivo miR-155 inhibition on the
expression of several M/M phenotypic markers, at differ-
ent time points after dMCAO. We used immunofluores-
cence staining and Western blot for these experiments,
since brain tissue disintegration (both without and with
fixation) affects detectability of cell surface markers and,
thus, accuracy of FACS-based analysis [46]. Immuno-
fluorescence staining of the histological sections did not
show visible differences in CD206 (C-type lectin mainly
present on the surface of macrophages and immature
dendritic cells) expression between inhibitor and control
groups, at any examined time point after dMCAO
(Additional file 1). These observations were later sup-
ported by Western blot analysis (Fig. 6c). CD206 was
expressed in hypertrophied Iba-1-positive cells, where it
displayed both membrane and intracellular localization.
These Iba1/CD206 expressing cells were mostly localized
to the glial scar region, at all examined time points after
dMCAO (Additional file 1). Similar distribution of
CD206 after stroke was previously reported by other au-
thors [47]. We then performed immunofluorescence
staining for other phenotypic markers including CD45
antigen (tyrosine phosphatase, type C, expressed in the
majority of hematopoietic cells, including leukocytes and
macrophages) and marker for active phagocytosis CD68
(glycoprotein that is highly expressed by monocytes and
tissue macrophages). Triple immunostaining for Iba-1,
CD45, and CD68 revealed visible differences in the inten-
sity of the expression of CD45 and CD68, between inhibi-
tors and controls, at 7 and 14 days after dMCAO. CD45-
and CD68-positive cells were exclusively localized to the
glial scar area; some of them infiltrated the infarct core re-
gion (Fig. 6a, left column of panels). At 7 days after
dMCAO, we observed distinctly lower intensity of CD45
and CD68 expression in the inhibitor group, as compared
to controls (Fig. 6a, two upper rows). Quantification of the
fluorescence intensity (Fig. 6b) and Western blot analysis
(Fig. 6c) confirmed this observation. In contrast to 7 days,
at 14 days after dMCAO, intensity of both CD45 and
CD68 was higher in the inhibitor group, as compared to
controls (Fig. 6a–c). No differences between groups were
observed at 21 days after dMCAO (not shown). Western
blot analysis confirmed that CD206 and Iba-1 expressions
were not significantly different between the inhibitor and
control groups, at any time point after dMCAO (Fig. 6c).
High-resolution immunofluorescence confocal micros-
copy also showed that CD45, as a cell membrane protein,
had a primarily cell surface localization, while CD68, as a
lysosomal/endosomal-associated membrane glycoprotein,
had mostly intracellular and weak cell membrane expres-
sion. In addition, Iba-1, CD45, and CD68 markers were
often expressed with different intensity in different cells
(Fig. 6a, right column of micrographs). This reflects diver-
sity in the expression of phenotypic markers in the injured
brain and the existence of multiple intermediate states of
M/M phenotype. Analysis of the phenotypic marker expres-
sion at different time points after dMCAO demonstrates
that miR-155 inhibition induces temporal shift in the ex-
pression of CD45 and CD68 markers. Reduced CD45/CD68
at 7 days corresponds to our EM data showing lower num-
ber of phagocytic cells in the inhibitor group. Most import-
antly, temporal changes in CD45 and CD68 levels in the
inhibitor group correlate with the time course of cytokine
suppression and activation at 7 and 14 days, respectively.
Discussion
In our previous study on the in vivo inhibition of miR-
155 after mouse dMCAO, we detected that the vascular
support achieved by anti-miR-155 injections at 7 days
after the experimental stroke played a critical role in the
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prevention of delayed neuronal loss in the peri-infarct
area at the later stages. Our previous analysis showed
significant (34 %) reduction of infarct size in miR-155
inhibitor-injected animals at 21 days after dMCAO. Re-
duced brain injury and preservation of brain tissue
reflected in efficient functional recovery of inhibitor-
injected animals: bilateral asymmetry/adhesive removal
and gait/locomotion tests demonstrated that the mice
from the inhibitor group regained their sensorimotor
deficits faster than controls [26]. Based on these data,
we assumed that vascular support achieved by miR-155
inhibition played a critical role in the prevention of
neuronal loss in the peri-infarct area and, thus, in the
improvement of functional outcome after stroke. We
proposed that increased blood flow and improved vascu-
lar integrity could be mainly attributed to miR-155
inhibition-induced stabilization of tight junction (TJ)
protein ZO1, via the upregulation of miR-155 target pro-
tein Rheb. Here, we hypothesized that, in addition to this
possible mechanism, downregulation of pro-inflammatory
miR-155 could improve stroke outcome by significantly
influencing a post-stroke inflammation. At 7 days after
dMCAO, there was a decreased mRNA and protein ex-
pression of pro-inflammatory cytokines CCL12 (also
known as monocyte chemotactic protein MCP-5) and
CXCL3 in the inhibitor group. Both cytokines are known
to trigger vascular inflammation via activation of mono-
cyte adhesion and migration through the vascular endo-
thelium, as well as atherosclerotic plaque formation [48,
49]. Seven days time point was also accompanied by sig-
nificant upregulation of miR-155-targeted proteins. miR-
155 direct targets SOCS-1, SOCS-6, and SHIP-1 inhibit
cytokine signaling, using multiple suppression mecha-
nisms [50, 51]. Another miR-155 target C/EBP-β pro-
motes the expression of anti-inflammatory cytokines
(including IL-10) and contributes to injury repair and neu-
roprotection [52, 53]. In the inhibitor samples from 7 days
after dMCAO, upregulation of SOCS-1 was accompanied
Fig. 6 Analysis of M/M phenotypic markers at different time points after dMCAO. a Coronal sections of the lesioned hemispheres of the inhibitor
and control mice brains, at seven (two upper rows of panels) and 14 days (two lower rows) after dMCAO. The sections were triple-immunostained with
anti-Iba-1 (red), anti-CD45 (blue), and anti-CD68 (green) antibodies. Representative merged and single-channel images depict part of the infarct core
(I, outlined with white dotted lines) and peri-infarct area of stroke. High magnification images demonstrate distribution of Iba-1, CD45, and CD68 in the glial
scar area (right panels). Imaging was performed using Zeiss LSM800 Airyscan confocal microscope, using single-scan and tile-scan image acquisitions. Bars:
from left to right: 100 and 10 μm. b Quantification of the corrected fluorescence intensity for CD45 and CD68 immunofluorescence staining in the inhibitor
(black bars) and control groups (white bar), at 7 and 14 days after dMCAO. N=5–6 mice per group/per time point, three brain sections per mouse. Error bars:
SEM; Student’s t test, *p< 0.05; **p< 0.01. c Representative Western blots and quantification analysis (graphs) of CD206, CD45, CD68, and Iba-1 expression in
lysates prepared from the lesioned cortical tissue of the animals from the inhibitor (black bars) and control (white bars) groups, at 7 and 14 days after dMCAO.
Graphs: optical density of each band was normalized to β-actin (loading control). N= 5–6 mice per group/per time point. Error bars: SEM; Student’s t
test, *p< 0.05
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by reduced STAT-3 phosphorylation. Cytokine signaling is
mediated via essential JAK/STAT pathway, in which STAT
phosphorylation is an indicator of cytokine signaling
activation [54]. SHIP-1 upregulation corresponds with de-
phosphorylation of its direct target protein Akt, demon-
strated earlier [26]. Together, these data indicate that at
7 days post-dMCAO, miR-155 inhibition potentially sup-
presses STAT-3- and PI-3K-mediated cytokine signaling
via its direct targets SOCS-1 and SHIP-1 activity. We
speculate that miR-155 inhibition-associated upregulation
of SOCS-1 and SHIP-1 could suppress number of differ-
ent cytokines, without affecting their mRNA or protein
levels. Altered cytokine expression and signaling (as com-
pared to control group) at 7 days after dMCAO was also
accompanied by alterations in perivascular M/M pheno-
type. Electron microscopy imaging revealed that, in con-
trast to inhibitors, peri-vascular microglia in the control
group was characterized by high phagocytic activity. En-
gulfment of blood vessels by phagocytic microglia results
in the degradation of blood vessels and the active break-
down of the BBB. It is suggested that phagocytic microglia
actively participate in the transfer of stroke-induced injury
in healthy neighboring tissue by the disassembly of blood
vessels and the resulting decrease in blood flow in the is-
chemic penumbra [44]. Thus, present EM data are in
good correlation with our previous findings that at 7 days
post-dMCAO, 30 % in control animals had disrupted tight
junctions, as opposed to only 9 % in the inhibitor group.
In addition, at the same time point after dMCAO, cerebral
blood flow in the peri-infarct area of the inhibitor animals
was significantly higher than in controls [26]. Immuno-
fluorescence analysis of the brain sections from 7 days after
dMCAO also confirmed decreased expression of leukocyte/
macrophage marker CD45 and active phagocytosis marker
CD68 in the anti-miR-155-injected group. Taken together
all these findings, we concluded that miR-155-induced sup-
pressed cytokine signaling at 7 days, accompanied by de-
creased M/M phagocytic activity, could contribute to
preservation of TJs observed at 7 days after dMCAO.
In the inhibitor group, expression of several important
cytokines lasted for as long as 14 days after dMCAO (in
contrast to a sharp decline after 7 days, detected in the
control samples). Sustained increase in expression of IL-
10 in the inhibitor-injected animals is in agreement with
recent investigations demonstrating suppression of this
cytokine by miR-155 [55]. This major anti-inflammatory
cytokine was shown to trigger anti-inflammatory re-
sponse beneficial for stroke outcome [41, 56]. Signifi-
cantly higher (as compared to controls) expression of
five other cytokines was also detected in the inhibitor
group at 14 days after dMCAO. These cytokines exhibiting
context-dependent dual action are implicated in having a
significant impact on neuroprotection and overall stroke
outcome. Il-4 (mostly regarded as anti-inflammatory
cytokine) and IL-5 were found to play a beneficial role in
brain repair, modulate microglial response, and suppress
post-stroke inflammation [57–59]. IL-6, apart from its well-
known pro-inflammatory function, can also exhibit neuro-
trophic and regenerative features following cerebral ischemia
[60, 61]. MIP-1α, a member of the CC chemokine subfamily,
is upregulated at early acute stages of cerebral ischemia and
may have a role in promoting inflammatory and/or repair
processes in ischemic brain [62]; at later stages, this
chemokine can also serve as a chemoattractant for stem cell
migration after ischemic injury [63]. The late (6 days after
stroke) peak of IL-17 was detected in other studies, propos-
ing a possible role of this cytokine in neovascularization after
MCAO [40]. High levels of IL-10 at 14 days after dMCAO
correlated with and could be induced by sustained elevation
of C/EBP-β detected at 7 and 14 days after dMCAO. In
addition, increased IL-10 levels at 14 days could be associ-
ated with the reduced suppression from SOCS-1 and SHIP-
1 [55]. STAT-3 activation at this time point could be
associated with (a) reduced suppression from SOCS-1 and
(b) sustained upregulation of IL-10. IL-10/STAT-3 pathway
activation triggers IL-10-mediated anti-inflammatory re-
sponse (AIR): upon IL-10-induced activation, STAT-3 stim-
ulates the expression of AIR factors, which specifically
suppress pro-inflammatory cytokine signaling [33, 64].
Based on the literature and our previous studies, miR-155
inhibition could potentiate IL-10/STAT-3-mediated AIR,
which could significantly contribute to improved post-stroke
recovery reported in our previous study [26].
Since miR-155 is implicated in the regulation of
macrophage differentiation and polarization toward anti-
inflammatory phenotype, we expected that miR-155 in-
hibition would lead to an increased expression of the
anti-inflammatory phenotype marker CD206. Instead,
we detected altered expression of CD45 and CD68
markers. Increased CD45 expression in the inhibitor
group (as compared to controls) at 14 days after stroke
may be associated with prolonged upregulation of IL-10,
since IL-10 was found to activate CD45 protein tyrosine
phosphatase [65]. CD45 is regarded as a negative regula-
tor of pro-inflammatory microglia activation associated
with MAPK signaling propagation and neuronal death
[66]. According to the literature, Iba-1/CD45-positive
macrophages expressing active phagocytosis marker
CD68 facilitate brain recovery process following LPS-
induced brain injury [67] and stroke [68] and mediate
neuroprotection in Alzheimer’s disease [69]. The upreg-
ulation of CD68 and, thus, phagocytic activity at 14 days
after dMCAO could facilitate removal of debris and
dead tissue, as well as promote revascularization, neuro-
protection, neurogenesis, and overall recovery [70].
Based on the literature, ameboid Iba-1-positive M/Ms
populating glial scar area are represented by macro-
phages, that infiltrated the site of the injury at early post-
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stroke stages, and resident microglia, that adopted
macrophage-like morphology in response to ischemia. Fol-
lowing cerebral ischemia, initially, pro-inflammatory M/Ms
undergo differentiation at later stages after stroke and ac-
quire anti-inflammatory pro-regenerative features, as de-
scribed in [71]. Based on our data, we propose that miR-155
inhibition at 48 h after stroke results in suppression of early
transient harmful actions of the activated M/Ms at 7 days,
followed by enhancement of their protective and reparative
actions at 14 days after dMCAO. In the present study, we
did not aim to phenotypically distinguish between the resi-
dent microglia and monocyte-derived infiltrated macro-
phages, or different types of infiltrated leukocytes. This issue
will be addressed in our upcoming studies involving
Cx3cr1GFP/+ /Ccr2RFP/+ transgenic mice; this approach will
minimize the artifacts associated with cell isolation/sorting
and, thus, assure a truly reliable separation of two different
cell types comprising the M/M population.
Conclusions
In summary, we found that in vivo inhibition of miR-155
following mouse experimental stroke significantly affects
the time course of the expression of major cytokines and
inflammation-associated molecules during a subacute
phase after dMCAO. This process could be mediated via
the changes in temporal expression of direct miR-155
target proteins. These findings contribute to understand-
ing of the molecular mechanisms underlying a positive
effect of miR-155 inhibition on the overall post-stroke
recovery reported in our previous studies.
Additional file
Additional file 1: Fluorescence microscopy analysis of CD206 expression at
different time points after dMCAO. Coronal sections of the lesioned
hemispheres of the mice subjected to dMCAO, at 48 h and 7, 14, and 21 days
after surgery. The sections were immunostained with anti-Iba-1 (red) and anti-
CD206 (green) antibodies; DAPI (blue) was used for nuclear staining. Left panels
depict part of the infarct core (I) and peri-infarct area of stroke. High
magnification images demonstrate distribution of Iba-1 and CD206-positive cells
in the peri-infarct area of stroke (middle panels) and glial scar (right panels).
Note that CD206 was mostly expressed in the Iba-1-positive ameboid M/Ms
populating glial scar area. Imaging was performed using Zeiss LSM510-META
confocal microscope, using single-scan and tile-scan image acquisitions. Bars:
from left to right: 100, 10, and 10 μm. (TIF 11901 kb)
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